Resveratrol inhibits macrophage and releases cytokines

Jun 18
09:04

2012

David Yvon

David Yvon

  • Share this article on Facebook
  • Share this article on Twitter
  • Share this article on Linkedin

Resveratrol can inhibit macrophage and releases cytokines. Recently, a study completed by the researchers finds that resveratrol can inhibit the tumor necrosis factor and interleukin-6 which are excessive released by alveolar macrophage

mediaimage

 It has brought a new hope for the treatment of chronic airway inflammation. So now many people and hospitals are eager to know resveratrol where to buy.

Chronic airway inflammation and airway remodeling is a common pathophysiological characteristics of a variety of lung diseases such as chronic obstructive pulmonary disease,Resveratrol inhibits macrophage and releases cytokines Articles bronchial asthma and other respiratory diseases, is characterized by a variety of inflammatory cells and factor interaction-induced airway disease. Macrophages play an extremely important role in the pathophysiology of macrophages in the bacterial products, smoke and other harmful ingredients such as formaldehyde, under the stimulation of the NO2 and other oxidation products migrate to the lung tissue and release of multiple cytokines such as TNF-alpha, IL-8, IL-6, IL-1, in turn, these cytokines can be chemotaxis of neutrophils, the migration of T cells, eosinophils and other lung tissue cells and inflammatory Cytokines are important factors to cause the serious injury of airway inflammation in chronic airway.

If the cells and the release of inflammatory cytokines can be effectively inhibited, it will reduce and alleviate damage of the airway. To investigate the effect of resveratrol on mouse alveolar macrophages release the cytokines IL-6, TNF-alpha, the researchers by mouse bronchoalveolar lavage in alveolar macrophages, divided into 5 groups were cultured in each group in culture 4,6,12,24-hour extract supernatant, ELISA determination of supernatant IL-6 and TNF-alpha content.

The study results from pharmaceutical raw materials suppliers show that in the stimulation of LPS, IL-6 is at a releasing peak in the 12 hours. At the peak, as concentration of resveratrol gradually increased, IL-6 levels decreased accordingly. And IL-6 levels of group E is significantly lower than A group with LPS. And with the stimulation of LPS in 6 hours, TNF-± is up to the releasing peak. At the peak, as the resveratrol concentration gradually increase, the TNF-± content is correspondingly decreased. And TNF- ± of group C, group D and group E are significantly lower than the A group. The results show that resveratrol can significantly inhibit the excessive release of inflammatory cytokines IL-6 and TNF-± for mouse alveolar macrophages. Thus it provides a theoretical basis for the treatment of chronic airway inflammation.

Source:http://www.cospcn.com